FDA Approves Akynzeo for Nausea, Vomiting Associated With Chemotherapy

The Food and Drug Administration Oct. 10 said it approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy.

Akynzeo is a fixed combination capsule comprised of two drugs, the FDA said. Oral palonosetron, approved in 2008, prevents nausea and vomiting during the acute phase (within the first 24 hours) after the start of cancer chemotherapy. Netupitant, a new drug, prevents nausea and vomiting during both the acute phase and delayed phase (from 25 to 120 hours) after the start of cancer chemotherapy, the agency said.

Akynzeo is distributed and marketed by Eisai Inc. of ...